P1-347 - Actual clinical use of Ramucirumab plus Paclitaxel at our hospital

Abstract

In Japan, use of ramucirumab (RAM) to gastric cancer approved for manufacture and marketing in March 2015. We decided to verify the results of actual clinical use. Besides, since treatment regimens for S-1 refractory relapse gastric cancer have not been determined, these patients at our hospital were also examined. We retrospectively analyzed gastric cancer patients who received RAM plus paclitaxel (PTX) between March 2015 and December 2016 at the The Japanese Red Cross Nagasaki Genbaku Hospital. Patients received RAM 8 mg/kg intravenously on days 1 and 15, plus PTX 80 mg/m2 intravenously on days 1, 8, and 15 of a 28-day cycle. The overall response rate (RR) by Response Evaluation Criteria in Solid Tumors guidelines version 1.1 and progression-free survival (PFS) were evaluated. In addition, the same analysis was conducted for S-1 refractory relapse gastric cancer at our hospital. Fourteen patients received RAM plus PTX. The RR for 8 assessable patients was 37.5% (95% Confidence Interval (CI), 8.5-75.5), the median PFS was 5.2 months, and the RR for 4 assessable patients was 50% (95% CI, 6.8-93.2), the median PFS was 5.0 months in S-1 refractory relapse gastric cancer patients who received RAM plus PTX as 2nd line. The results of actual clinical use of RAM plus PTX at our hospital were also the same as previously reported in RAINBOW trial. Further prospective evaluations for S-1 refractory relapse gastric cancer are warranted.